menu
    • menu
    [{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Tildrakizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tildrakizumab

    Menu

    Tildrakizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Almirall

                            Spain arrow
                            Pharma Live Expo
                            Not Confirmed

                            Almirall

                            Spain arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Almirall, The First to Assess Wellbeing in a Dermatology Clinical Study

                            Details : Ilumetri (tildrakizumab) is a humanized mAb that targets the p19 subunit of IL-23 and inhibits the release of proinflammatory cytokines and chemokines with limited impact on the rest of the immune system. It is indicated for adults with moderate-to-sever...

                            Product Name : Ilumetri

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 04, 2023

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            Pharma Live Expo
                            Not Confirmed

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sun Pharma Gets China NMPA Approval For ILUMETRI To Treat Moderate-To-Severe Plaque Psoriasis

                            Details : Ilumetri (tildrakizumab), a humanized, anti-IL-23p19 monoclonal antibody designed to selectively block cytokine IL-23, has been approved by the NMPA for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic ther...

                            Product Name : Ilumya

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 30, 2023

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            Pharma Live Expo
                            Not Confirmed

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sun Pharma to Present Clinical Data Abstracts for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-S...

                            Details : The data to be highlighted shows ILUMYA treatment in patients with moderate-to-severe plaque psoriasis in real-world practice resulted in significant improvement from baseline disease activity and baseline quality of life with no new safety concerns.

                            Product Name : Ilumya

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 24, 2022

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            Pharma Live Expo
                            Not Confirmed

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sun Pharma Announces the Launch of ILUMYA® (tildrakizumab) for Treatment of Plaque Psoriasis in Japan

                            Details : ILUMYA is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL23 and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of proinflammatory cytokines and chemokines.

                            Product Name : Ilumya

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 23, 2020

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            Pharma Live Expo
                            Not Confirmed

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA™ for the Middle East and North Afri...

                            Details : Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of ILUMYA™ in all MENA markets and Sun Pharma will be responsible for product supply.

                            Product Name : Ilumya

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            June 15, 2020

                            Lead Product(s) : Tildrakizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth